Humanigen Inc at Guggenheim Vaccine and Infectious Disease Conference (Virtual) Transcript
Good morning, everyone. On behalf of Seamus Fernandez, myself, I'd like to welcome everybody to the first day of our Second Annual Vaccines and Infectious Disease Day. I'm Evan Wang, member of the Guggenheim's global biopharmaceuticals team, and kicking off this morning is Humanigen. I'm joined by Humanigen's Dale Chappell, Chief Scientific Officer.
Humanigen is developing lenzilumab as anti-human GM-CSF monoclonal antibody for the treatment of cytokine release syndrome associated with COVID-19, CAR-T cell therapy and acute graft-versus-host disease associated with bone marrow transplants. I've asked Dale to provide an overview of the Company, and then we will jump right to Q&A. Dale?
Thanks, Evan. Good morning, everyone, and thanks, Evan, for hosting us today. So the goal with this first portion will just be to provide a brief overview of Humanigen to folks that are new to the story. We do have some updates for folks who are -- have been following
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |